The Small Biotech Innovation Act aims to support small biotechnology companies by creating an exception for them from the Medicare drug price negotiation program. This program is designed to help lower the prices of prescription drugs for Medicare beneficiaries. The legislation recognizes the unique challenges faced by small biotech manufacturers, particularly those heavily invested in research and development. One of the key provisions of the Act is the establishment of criteria that define which small biotech manufacturers can qualify for this exception.